George Coukos - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock George Coukos's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
George Coukos
Verified
Senior Editor, Immuno-Oncology Technology
Lausanne
Beats
Culture and Social Media
Advertising and brandwashing.
Content
By Arthur Mulvey, George Coukos| Nature Verified AbstractThe immune-related adverse events associated with chimeric antigen receptor (CAR)-T cell therapy result in substantial morbidity as well as considerable cost to the health-care system, and can limit the use of these treatments. Current therapeutic strategies to manage immune-related adverse events include interleukin-6 receptor (IL-6R) blockade and corticosteroids.
By Anais Elewaut, Felix Bayerl, Martin Schönlein, Trung Nguyen, Trung Nguyễn, Francesco Andreatta, Milica Vulin, Felix Holstein, Denarda Dangaj Laniti, David Barras, George Coukos, Camelia Quek, Johannes Zuber, Göran Jonsson, Jan P. Böttcher, Sakari Vanharanta, Guillem Estivill, Jonas Bayerl| Nature Verified AbstractThe tumour microenvironment is programmed by cancer cells and substantially influences anti-tumour immune responses1,2. Within the tumour microenvironment, CD8+ T cells undergo full effector differentiation and acquire cytotoxic anti-tumour functions in specialized niches3,4,5,6,7. Although interactions with type 1 conventional dendritic cells have been implicated in this process3,4,5,8,9,10, the underlying cellular players and molecular mechanisms remain incompletely understood.
By Arthur Mulvey, George Coukos| Nature Verified AbstractThe immune-related adverse events associated with chimeric antigen receptor (CAR)-T cell therapy result in substantial morbidity as well as considerable cost to the health-care system, and can limit the use of these treatments. Current therapeutic strategies to manage immune-related adverse events include interleukin-6 receptor (IL-6R) blockade and corticosteroids.
Company Info
Immuno-Oncology Technology